JNCCN 360 - Immunotherapy

Advertisement

Advertisement

Sumanta K. Pal, MD, on Renal Cancer Immunotherapy: Latest Developments

Abby Fuoto, RN, ANP, on Managing the Adverse Events of Cetuximab

Nancy U. Lin, MD, on the HER2CLIMB Trial: Triplet Regimen for Metastatic Breast Cancer

Recent

SOHO 2020: Debulking Regimens Prior to Venetoclax Therapy for CLL

SOHO 2020: Fixed-Volume Isatuximab in Resistant Multiple Myeloma

ESMO 2020: Targeting PD-1 in Merkel Cell Carcinoma

SOHO 2020: Chemotherapy-Free Combination Therapy for CLL Under Study in Phase III Trial

Published

Medical Literature

How Comorbidities May Affect Response to Idelalisib-Based Therapy in CLL

Fixed-Duration Combination Regimen Under Study in CLL

Response to Neoadjuvant Immunotherapy for Rectal Cancer: Case Series

Can Immunoglobulin Expression Predict Survival in Patients With AML?

Ongoing

Modest Responses With Immunotherapy Combo for Advanced Ovarian Cancer

Emerging Considerations in Triple-Negative Breast Cancer: Focus on Immunotherapy

BCOP Test-Advances in Targeted Therapy and Immunotherapy For The Treatment of Kidney Cancer

NCCN Pharmacy Updates: Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer

Available

Clinical Trials

Center for Immunotherapy Clinical Research Trials

Cancer Research Institute Immunotherapy Clinical Trials

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

ClinicalTrials.gov Immunotherapy

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.